ANTI-CANCER DRUGS
·
2021
·Vol. 32
·期 7
·727
·
IF 2.248
Zhang Zuo-yan,Dong Shu-min,Liu Ye-han,Zhang Man-man,Zhang Jian-kang,Zhu Hua-jian,Shao Jia-an,Liu Hua-qing,Li Yang-ling,Zhang Chong,Zeng Ling-hui
Vinpocetine is widely used to treat cerebrovascular diseases. However, the effect of vinpocetine to treat hepatocellular carcinoma (HCC) has not been investigated. In this study, we revealed that vinpocetine was associated with antiproliferative activity in HCC cells, but induced cytoprotective autophagy, which restricted its antitumor activity. Autophagy inhibitors improved the antiproliferative activity of vinpocetine in HCC cells. Sorafenib is effective to treat advanced HCC, but the effect of autophagy induced by sorafenib is indistinct. We demonstrated vinpocetine plus sorafenib suppressed the cytoprotective autophagy activated by vinpocetine in HCC cells and significantly induced apoptosis and suppressed cell proliferation in HCC cells. In addition, vinpocetine plus sorafenib activates glycogen synthase kinase 3β (GSK-3β) and subsequently inhibits cytoprotective autophagy induced by vinpocetine in HCC cells. Meanwhile, overexpression of GSK-3β was efficient to increase the apoptosis induced by vinpocetine plus sorafenib in HCC cells. Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3β and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3β signaling axis. Thus, vinpocetine may be a potential candidate for sorafenib sensitization and HCC treatment, and our results may help to elucidate more effective therapeutic options for HCC patients with sorafenib resistance.
✓ 已验证
产品关联
DOI
PubMed
高影响因子
CRYSTAL GROWTH & DESIGN
·
2024
·
IF 3.2
Shengzheng Guo,Yuechao Cao,Yuxin Zhang,Yan Wang,Zhenguo Gao,Junbo Gong
Inhaled drug delivery has garnered increasing attention due to its inherent advantages including rapid onset of action, targeted delivery, high bioavailability, and reduced side effects, which holds promise for the treatment of localized lung diseases and systemic diseases. The currently dominant technologies for the preparation of inhalants are air flow pulverization, media milling, and spray drying, which encounter challenges such as inaccurate particle size control, inefficiency, instability, and difficulties in scaling up. The present study proposes a freeze-dissolving technique (FDT) for the preparation of inhalable microcrystals, comprising two essential steps: rapid freezing of microdroplets into iced pellets within seconds and subsequent dissolution of a solvent in the iced pellets to release the microcrystals in a suspension. By employing the FDT technique, griseofulvin, a representative inhalant, was successfully engineered into a bipyramidal morphology with a targeted particle size (<5 μm), minimal agglomeration (<3%), and an aspect ratio below 2, in which the solvent and stabilizer systems played pivotal roles in facilitating or impeding nucleation and crystal growth processes. To verify the universality of the FDT, six other typical inhalant preparation processes were successfully developed based on the FDT with a controllable crystal size between 1 and 10 μm. Furthermore, three out of the aforementioned seven model substances were randomly selected, and their preparation was scaled up by a factor of 100, yielding consistent results with those obtained at a smaller test scale. This study outlines the freeze-dissolving mechanism in ultrafine crystal formation and demonstrates that the FDT is a robust and scalable approach for the production of inhalants.
✓ 已验证
产品关联
DOI
高影响因子
eLife
·
2025
·
IF 0
Chong Zhang,Zuoyan Zhang,Yueyi Wu,Yuchen Wu,Jing Cheng,Kaizhi Luo,Zhidi Li,Manman Zhang,Jian Wang,Xuesen Zhang,Yangling Li
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, and the prognosis is poor due to distant metastasis. Thus, there is an urgent need to discover novel therapeutic targets and strategies to overcome metastasis. A series of in vitro and in vivo phenotype experiments were performed to investigate the role of phosphodiesterase 1A (PDE1A) in NSCLC. The RNA binding protein immunoprecipitation (RIP) assay, messenger RNA (mRNA) stability assay, and LC-MS/MS were performed to investigate the molecular mechanisms of PDE1A in NSCLC progression. PDE1A has been shown to promote metastasis and epithelial-mesenchymal transition (EMT) progression of NSCLC. In addition, NSCLC cells overexpressing PDE1A promoted angiogenesis by regulating exosome release. IL-6/JAK/STAT3 signaling pathway was highly enriched in PDE1A-coexpressed genes, and PDE1A promoted NSCLC metastasis by activating the STAT3 pathway. GO enrichment analysis of PDE1A-interacting genes showed that PDE1A might interact with YTHDF2 and participate in m6A-containing RNA binding. The binding between PDE1A and YTHDF2 was verified, and PDE1A regulated the STAT3 pathway by interacting with YTHDF2. The mechanism of the YTHDF2/PDE1A complex in regulating the STAT3 pathway was predicted by overlapping YTHDF2-interacting RNAs and genes coexpressed with YTHDF2 and STAT3. The interactions between YTHDF2 and target mRNAs were predicted, and there were three predicted targets of YTHDF2 with high scores: NRF2, SOCS2, and MET. Indeed, PDE1A interacted with YTHDF2, destabilized SOCS2, and activated the STAT3 pathway. Mechanistic data uncover a novel PDE1A/YTHDF2/STAT3 axis driving NSCLC metastasis and suggest potential therapeutic strategies for metastatic disease.
✓ 已验证
产品关联
DOI
PubMed
危险品化学品经营许可证（带存储）